Orion PharmaDHA:ORIONPHARM +3.02%71 EBITDA Margin % is 9.43% as of Mar. 2026, which is 50% below its 10-year median of 18.75. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 71/100 and a GF Value™ of BDT20.19 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 420 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 71.9% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Orion Pharma's EBITDA for the
three
months ended in Mar. 2026 was BDT140 Mil. Orion Pharma's Revenue for the
three
months ended in Mar. 2026 was BDT1,487 Mil. Therefore, Orion Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 9.43%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Orion Pharma EBITDA Margin % Related Terms
Orion Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Orion Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: EBITDA Margin % Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma EBITDA Margin % vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Orion Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a EBITDA Margin % of 9.43% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Orion Pharma and its competitors. This is 50% below median its historical median of 18.75. Over the past decade, Orion Pharma's EBITDA Margin % has ranged from 11.36 to 32.03. According to the industry distribution chart, Orion Pharma ranks #302 out of 420 companies in the Utilities - Independent Power Producers industry, placing it in the top 71.9%.
Is Orion Pharma's EBITDA Margin % too high?
Orion Pharma's current EBITDA Margin % of 9.43% is 50% below median its 10-year median of 18.75. Over the past 10 years, this metric has ranged from a low of 11.36 to a high of 32.03. The Utilities - Independent Power Producers industry median EBITDA Margin % is 27.77. Orion Pharma's value of 9.43% is 66% below this industry median. Based on the distribution chart, Orion Pharma ranks #302 out of 420 companies in the Utilities - Independent Power Producers industry, which is below the industry midpoint. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's EBITDA Margin % compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #302 out of 420 companies for EBITDA Margin %. This places Orion Pharma in the lower half of its industry. The industry median EBITDA Margin % is 27.77. Orion Pharma's value of 9.43% is 66% below this benchmark. Historically, Orion Pharma's own EBITDA Margin % has ranged from 11.36 to 32.03 over the past decade. While the company's 10-year median is 18.75 vs. the industry median of 27.77, Orion Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for an Utilities - Independent Power Producers company?
The median EBITDA Margin % among Utilities - Independent Power Producers companies is 27.77, based on 420 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current EBITDA Margin % of 9.43% is 66% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median EBITDA Margin % is 27.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current EBITDA Margin % is 9.43%, which is 50% below median its own 10-year median of 18.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.19, compared to a current price of BDT30.70 — trading 52.1% above its estimated fair value. The current EBITDA Margin % is 9.43%, which is 50% below median its 10-year median of 18.75 and 66% below the Utilities - Independent Power Producers industry median of 27.77. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current EBITDA Margin % is 9.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT30.70 is trading 52.1% above its estimated GF Value™ of BDT20.19.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
EBITDA Margin %: 9.43% (50% below median its 10-year median of 18.75)
GF Value™: BDT20.19 vs. price of BDT30.70 (52.1% above fair value)
Industry Position: 66% below the Utilities - Independent Power Producers median (#302 of 420)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
71GF Score
Get the complete analysis for DHA:ORIONPHARM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
